C elegans

Magnitude Biosciences has closed a fourth round of investment to accelerate the scaling of its business providing C. elegans research services.   A total investment of £500,000 will be made by longstanding investors the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by Northstar Ventures, and Saker Capital.   […]

In this article, Professor Zheng-Zhu (Principal Investigator and Director of Metabolomics Research Center at the Shanghai Institute of Organic Chemistry) and Lucy Woods (Business Unit Manager for Phenomics and Metabolomics at Bruker Daltonics), summarise the most important configurations and options for partnering IMS–MS with liquid chromatography (LC) and show how this approach could revolutionise metabolome […]

David Weinkove, CEO Magnitude Biosciences, examines the untapped microbiome and its potential into helping unlock new therapies. Why the microbiome? The human microbiome is an important emerging field for drug discovery that harbours an array of life-changing medicines for patients. Whilst it is increasingly acknowledged that the human microbiome holds great promise for healthcare, its […]